1) First-line treatment of metastatic or recurrent breast cancer.
2) Second-line treatment of metastatic breast cancer after failure of standard chemotherapy.
1) First-line treatment of locally advanced or metastatic non-small cell lung cancer.
1) First-line treatment in combination with other chemotherapeutic agents.
The new formulation is free from toxic surfactant and allows significantly higher dosing of paclitaxel to the patients.
(The goal of polymeric micelle technology is to enhance solublization of water insoluble drugs to facilitate formulation of therapeutcally more effective products)